loading
Akero Therapeutics Inc stock is traded at $32.49, with a volume of 232.19K. It is up +1.50% in the last 24 hours and up +15.19% over the past month. Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.
See More
Previous Close:
$32.05
Open:
$31.76
24h Volume:
232.19K
Relative Volume:
0.48
Market Cap:
$2.20B
Revenue:
-
Net Income/Loss:
$-179.27M
P/E Ratio:
-12.69
EPS:
-2.56
Net Cash Flow:
$-155.88M
1W Performance:
+2.52%
1M Performance:
+15.19%
6M Performance:
+65.47%
1Y Performance:
+123.12%
1-Day Range:
Value
$31.12
$32.60
1-Week Range:
Value
$30.12
$32.95
52-Week Range:
Value
$13.39
$37.00

Akero Therapeutics Inc Stock (AKRO) Company Profile

Name
Name
Akero Therapeutics Inc
Name
Phone
650-487-6488
Name
Address
601 GATEWAY BOULEVARD, SUITE 350, SOUTH SAN FRANCISCO, CA
Name
Employee
58
Name
Twitter
@akerotx
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
AKRO's Discussions on Twitter

Akero Therapeutics Inc Stock (AKRO) Upgrades & Downgrades

Date Action Analyst Rating Change
Apr-22-24 Resumed BofA Securities Neutral
Sep-19-23 Initiated Cantor Fitzgerald Overweight
Aug-28-23 Initiated UBS Buy
Jan-27-23 Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-14-22 Upgrade Evercore ISI In-line → Outperform
Oct-19-21 Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-10-21 Initiated BofA Securities Buy
Feb-26-21 Initiated Guggenheim Buy
Sep-10-20 Initiated Morgan Stanley Overweight
Jul-20-20 Reiterated H.C. Wainwright Buy
Jul-07-20 Initiated Chardan Capital Markets Buy
Jul-01-20 Reiterated H.C. Wainwright Buy
Mar-02-20 Initiated H.C. Wainwright Buy
Feb-10-20 Initiated Canaccord Genuity Buy
Jul-15-19 Initiated Evercore ISI Outperform
Jul-15-19 Initiated JP Morgan Overweight
Jul-15-19 Initiated Jefferies Buy
Jul-15-19 Initiated ROTH Capital Buy
View All

Akero Therapeutics Inc Stock (AKRO) Latest News

pulisher
11:33 AM

Akero Therapeutics COO sells $1.6 million in stock - Investing.com India

11:33 AM
pulisher
10:08 AM

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $1,601,104.12 in Stock - MarketBeat

10:08 AM
pulisher
09:19 AM

Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock By Investing.com - Investing.com Canada

09:19 AM
pulisher
09:18 AM

Akero Therapeutics CEO Andrew Cheng sells $3.4 million in stock - Investing.com India

09:18 AM
pulisher
Nov 04, 2024

abrdn plc Sells 75,879 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Sells 4,515 Shares of Stock - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

Akero Therapeutics chief development officer sells $651,960 in stock By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Akero Therapeutics chief development officer sells $651,960 in stock - Investing.com

Nov 01, 2024
pulisher
Oct 29, 2024

Akero Therapeutics (NASDAQ:AKRO) Trading Up 5.8%Here's What Happened - MarketBeat

Oct 29, 2024
pulisher
Oct 27, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Decline in Short Interest - MarketBeat

Oct 27, 2024
pulisher
Oct 21, 2024

Akero Therapeutics to Present Data Reinforcing the Efficacy - GlobeNewswire

Oct 21, 2024
pulisher
Oct 21, 2024

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024 - StockTitan

Oct 21, 2024
pulisher
Oct 20, 2024

Akero Therapeutics Insiders Sell US$1.2m Of Stock, Possibly Signalling Caution - Simply Wall St

Oct 20, 2024
pulisher
Oct 19, 2024

(AKRO) Proactive Strategies - Stock Traders Daily

Oct 19, 2024
pulisher
Oct 18, 2024

Andrew Cheng Sells 24,992 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock - MarketBeat

Oct 18, 2024
pulisher
Oct 18, 2024

Akero Therapeutics CEO Andrew Cheng sells $2.88 million in stock By Investing.com - Investing.com Canada

Oct 18, 2024
pulisher
Oct 18, 2024

Akero Therapeutics chief development officer sells $636,490 in stock By Investing.com - Investing.com South Africa

Oct 18, 2024
pulisher
Oct 18, 2024

Akero Therapeutics chief development officer sells $636,490 in stock - Investing.com India

Oct 18, 2024
pulisher
Oct 17, 2024

State Street Corp's Strategic Reduction in Akero Therapeutics Inc Shares - GuruFocus.com

Oct 17, 2024
pulisher
Oct 17, 2024

Akero therapeutics COO Jonathan Young sells $1.2 million in stock By Investing.com - Investing.com Australia

Oct 17, 2024
pulisher
Oct 17, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Purchased by Rheos Capital Works Inc. - MarketBeat

Oct 17, 2024
pulisher
Oct 17, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Sees Significant Decrease in Short Interest - MarketBeat

Oct 17, 2024
pulisher
Oct 16, 2024

Akero therapeutics COO Jonathan Young sells $1.2 million in stock - Investing.com

Oct 16, 2024
pulisher
Oct 16, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 6,136 Shares - MarketBeat

Oct 16, 2024
pulisher
Oct 16, 2024

Akero Therapeutics (AKRO): Leading the Charge in MASH Treatment with Efruxifermin - Insider Monkey

Oct 16, 2024
pulisher
Oct 15, 2024

Akero Therapeutics, Inc. (AKRO): A Visionary Small-Cap Stock Pick by Hedge Funds - Insider Monkey

Oct 15, 2024
pulisher
Oct 15, 2024

Should investors be concerned about Akero Therapeutics Inc (AKRO)? - US Post News

Oct 15, 2024
pulisher
Oct 15, 2024

Non Alcoholic Fatty Liver Disease (NAFLD) Clinical Trials 2024: EMA, PDMA, FDA Approvals, Medication, Statistics, Drugs, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail

Oct 15, 2024
pulisher
Oct 14, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Shares Sold by Dimensional Fund Advisors LP - MarketBeat

Oct 14, 2024
pulisher
Oct 12, 2024

10 Most Promising Small-Cap Stocks According to Hedge Funds - Insider Monkey

Oct 12, 2024
pulisher
Oct 12, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat

Oct 12, 2024
pulisher
Oct 10, 2024

The Manufacturers Life Insurance Company Purchases 22,195 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Oct 10, 2024
pulisher
Oct 09, 2024

Akero Therapeutics Inc [AKRO] Investment Appeal on the Rise - Knox Daily

Oct 09, 2024
pulisher
Oct 09, 2024

AKRO’s 2023 Market Dance: Up 20.56% – Time to Invest? - The InvestChronicle

Oct 09, 2024
pulisher
Oct 08, 2024

Akero Therapeutics (NASDAQ:AKRO) Shares Up 4.2%Here's Why - MarketBeat

Oct 08, 2024
pulisher
Oct 07, 2024

A better buy-in window may exist right now for Akero Therapeutics Inc (AKRO) - SETE News

Oct 07, 2024
pulisher
Oct 04, 2024

A company insider recently sold 10,000 shares of Akero Therapeutics Inc [AKRO]. Should You Sale? - Knox Daily

Oct 04, 2024
pulisher
Oct 04, 2024

Algert Global LLC Decreases Holdings in Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Oct 04, 2024
pulisher
Oct 03, 2024

Akero Therapeutics COO sells $281,770 in company stock - Investing.com

Oct 03, 2024
pulisher
Oct 03, 2024

Akero Therapeutics, Inc. (NASDAQ:AKRO) COO Sells $281,800.00 in Stock - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

Is Akero Therapeutics Inc (AKRO) a good investment opportunity? - US Post News

Oct 02, 2024
pulisher
Oct 01, 2024

The Potential Rise in the Price of Akero Therapeutics Inc (AKRO) following insiders activity - Knox Daily

Oct 01, 2024
pulisher
Sep 30, 2024

INVESTOR ACTION NOTICE: Moore Law PLLC Encourages Investors in Akero Therapeutics, Inc. to Contact Law Firm - Longview News-Journal

Sep 30, 2024
pulisher
Sep 30, 2024

Top investors say Akero Therapeutics Inc (AKRO) ticks everything they need - SETE News

Sep 30, 2024
pulisher
Sep 30, 2024

Perceptive Advisors LLC Purchases 112,426 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) - MarketBeat

Sep 30, 2024
pulisher
Sep 30, 2024

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference - StockTitan

Sep 30, 2024
pulisher
Sep 28, 2024

Akero Therapeutics Inc (AKRO) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register

Sep 28, 2024
pulisher
Sep 28, 2024

(AKRO) Investment Analysis and Advice - Stock Traders Daily

Sep 28, 2024
pulisher
Sep 27, 2024

DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Beha - GuruFocus.com

Sep 27, 2024
pulisher
Sep 27, 2024

A company insider recently sold 5,500 shares of Akero Therapeutics Inc [AKRO]. Should You Sale? - Knox Daily

Sep 27, 2024
pulisher
Sep 27, 2024

Akero Therapeutics (NASDAQ:AKRO) Trading Down 2.7% - MarketBeat

Sep 27, 2024

Akero Therapeutics Inc Stock (AKRO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.30
price up icon 1.75%
$75.59
price down icon 0.20%
$374.10
price down icon 0.29%
$52.67
price down icon 0.85%
$207.67
price up icon 0.20%
$108.59
price up icon 0.02%
Cap:     |  Volume (24h):